Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Here’s Why Tao Value Loves Gilead Sciences (GILD) Stock

Tao Value recently released its Q1 2020 Investor Letter, a copy of which you can download here. The fund posted a return of -12.96% for the quarter, outperforming their benchmark, the MSCI All Country World Index (ACWI) which returned -21.05% in the same quarter.

In the said letter, Tao Value highlighted a few stocks and Gilead Sciences Inc (NASDAQ:GILD) is one of them. Gilead is a biopharmaceutical company based in California. Year-to-date, GILD stock gained 19.8% and on May 5th it had a closing price of $79.14. Its market cap is of $98.1 billion. Here is what Tao Value said:

“Gilead Sciences. (ticker: GILD) is one of our long term “great business at reasonable price” holding since 2017 Q31 . It had a major acquisition of Kite Pharmaceutical (for its CAR-T therapy) since, but the end market of the subsequent commercial drug – Yescarta turned out to be much smaller than anticipated. The stock price went nowhere since. It came to the spotlight this past quarter as its old Ebola drug, Remdesivir, has the highest hope to be an effective therapeutic against COVID-19. As my original thesis laid out, what attracted me the most was the mission (part of the Tao factor) of this company. The management decision making during this pandemic displayed exactly what convinced me initially. E.g. on a leaked internal townhall meeting video in January (when COVID-19 affected primarily China only), one employee asked the CEO Daniel O’Day what the company thinks of Wuhan Institute of Virology applied a patent with China authority for using donated Remdesivir to treat COVID19 (which was rejected later). O’Day expressed no bitterness rather stated that Gilead will focus on doing what is right by putting the patient first. This “patient first” mission was resonated by later decisions like 1) voluntarily asking to rescind an FDA granted orphan drug designation for Remdesivir (giving up revenue), 2) ramping up production when still in experiment (potential wasted cost) & 3) gifting up to 1.5 million doses (giving up revenue). With such a mission and strong cash generating ability from existing HIV & HCV drugs, Gilead remains a very safe and promising asset in biotechnology industry.”

In Q4 2019, the number of bullish hedge fund positions on GILD stock increased by about 2% from the previous quarter (see the chart here).

Disclosure: None. This article is originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.